Long-Term Follow-Up Analysis of a Phase II Study of Durvalumab Plus Concurrent Definitive Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (WJOG11619L: DOLPHIN Study) (WJOG11619LFS)

Long-Term Follow-Up Analysis of a Phase II Study of Durvalumab Plus Concurrent Definitive Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (WJOG11619L: DOLPHIN Study) (WJOG11619LFS) - WJOG11619LFS (DOLPHIN-LTFU)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061522

Enrollment

Registered

2026-05-12

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in WJOG11619L who received at least one course of durvalumab (n=34) and did not meet any of the exclusion criteria will be included.

Exclusion criteria

Exclusion criteria: - Patients who have declined participation in this study through an opt-out process based on publicly available information - Patients judged to be unsuitable for inclusion in this study by the principal investigator

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Overall survival, late toxicity, patterns of recurrence, subsequent treatments, and differences in treatment efficacy according to patient characteristics and PD-L1 expression (exploratory subgroup analyses)	—

Countries

Japan

Contacts

Public ContactNaoki Ishizuka

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results